Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,17884739,flow rate,"The mobile phase consisting of a mixture of acetonitrile and 0.05 mM formic acid (50:50 v/v, pH 3.5) was delivered at a flow rate of 0.25 ml/min.",Simultaneous determination of fixed dose combination of nebivolol and valsartan in human plasma by liquid chromatographic-tandem mass spectrometry and its application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17884739/),[ml] / [min],0.25,3007,DB04861,Nebivolol
,22491307,flow rate,Analysis was carried out under isocratic conditions at a flow rate of 1.5 mL/min and at room temperature using a fluorescence detector with excitation at 288 nm and emission at 310 nm.,Quantification of nebivolol hydrochloride in human plasma by liquid chromatography using fluorescence detection: Use in pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22491307/),[ml] / [min],1.5,13639,DB04861,Nebivolol
,22491307,recovery,The average recovery of nebivolol from spiked human plasma was 98.4 ± 3.3%.,Quantification of nebivolol hydrochloride in human plasma by liquid chromatography using fluorescence detection: Use in pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22491307/),%,98.4,13640,DB04861,Nebivolol
,9131955,AUC,"Cimetidine significantly (p < 0.05) increased the AUC [mean +/- s.d. (95% C.I. of differences in mean)] for unchanged (+/-)-nebivolol [7.76 +/- 3.07 ng ml-1 h with placebo; 11.50 +/- 5.40 (1.75, 8.76) ng ml-1 h with cimetidine], (+)-nebivolol plus its hydroxylated metabolites [73.0 +/- 18.0 ng ml-1 h with placebo; 91.5 +/- 25.7 (1.0, 23.1) ng ml-1 h with cimetidine] and (-)-nebivolol plus its hydroxylated metabolites [101 +/- 32 ng ml-1 h with placebo; 123 +/- 38 (3.3, 27.0) ng ml-1 h with cimetidine].",A pharmacokinetic and pharmacodynamic interaction study between nebivolol and the H2-receptor antagonists cimetidine and ranitidine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9131955/),[h·ng] / [ml],7.76,35040,DB04861,Nebivolol
,9131955,AUC,"Cimetidine significantly (p < 0.05) increased the AUC [mean +/- s.d. (95% C.I. of differences in mean)] for unchanged (+/-)-nebivolol [7.76 +/- 3.07 ng ml-1 h with placebo; 11.50 +/- 5.40 (1.75, 8.76) ng ml-1 h with cimetidine], (+)-nebivolol plus its hydroxylated metabolites [73.0 +/- 18.0 ng ml-1 h with placebo; 91.5 +/- 25.7 (1.0, 23.1) ng ml-1 h with cimetidine] and (-)-nebivolol plus its hydroxylated metabolites [101 +/- 32 ng ml-1 h with placebo; 123 +/- 38 (3.3, 27.0) ng ml-1 h with cimetidine].",A pharmacokinetic and pharmacodynamic interaction study between nebivolol and the H2-receptor antagonists cimetidine and ranitidine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9131955/),[h·ng] / [ml],11.50,35041,DB04861,Nebivolol
,9131955,AUC,"Cimetidine significantly (p < 0.05) increased the AUC [mean +/- s.d. (95% C.I. of differences in mean)] for unchanged (+/-)-nebivolol [7.76 +/- 3.07 ng ml-1 h with placebo; 11.50 +/- 5.40 (1.75, 8.76) ng ml-1 h with cimetidine], (+)-nebivolol plus its hydroxylated metabolites [73.0 +/- 18.0 ng ml-1 h with placebo; 91.5 +/- 25.7 (1.0, 23.1) ng ml-1 h with cimetidine] and (-)-nebivolol plus its hydroxylated metabolites [101 +/- 32 ng ml-1 h with placebo; 123 +/- 38 (3.3, 27.0) ng ml-1 h with cimetidine].",A pharmacokinetic and pharmacodynamic interaction study between nebivolol and the H2-receptor antagonists cimetidine and ranitidine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9131955/),[h·ng] / [ml],73.0,35042,DB04861,Nebivolol
,9131955,AUC,"Cimetidine significantly (p < 0.05) increased the AUC [mean +/- s.d. (95% C.I. of differences in mean)] for unchanged (+/-)-nebivolol [7.76 +/- 3.07 ng ml-1 h with placebo; 11.50 +/- 5.40 (1.75, 8.76) ng ml-1 h with cimetidine], (+)-nebivolol plus its hydroxylated metabolites [73.0 +/- 18.0 ng ml-1 h with placebo; 91.5 +/- 25.7 (1.0, 23.1) ng ml-1 h with cimetidine] and (-)-nebivolol plus its hydroxylated metabolites [101 +/- 32 ng ml-1 h with placebo; 123 +/- 38 (3.3, 27.0) ng ml-1 h with cimetidine].",A pharmacokinetic and pharmacodynamic interaction study between nebivolol and the H2-receptor antagonists cimetidine and ranitidine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9131955/),[h·ng] / [ml],91.5,35043,DB04861,Nebivolol
,9131955,AUC,"Cimetidine significantly (p < 0.05) increased the AUC [mean +/- s.d. (95% C.I. of differences in mean)] for unchanged (+/-)-nebivolol [7.76 +/- 3.07 ng ml-1 h with placebo; 11.50 +/- 5.40 (1.75, 8.76) ng ml-1 h with cimetidine], (+)-nebivolol plus its hydroxylated metabolites [73.0 +/- 18.0 ng ml-1 h with placebo; 91.5 +/- 25.7 (1.0, 23.1) ng ml-1 h with cimetidine] and (-)-nebivolol plus its hydroxylated metabolites [101 +/- 32 ng ml-1 h with placebo; 123 +/- 38 (3.3, 27.0) ng ml-1 h with cimetidine].",A pharmacokinetic and pharmacodynamic interaction study between nebivolol and the H2-receptor antagonists cimetidine and ranitidine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9131955/),[h·ng] / [ml],101,35044,DB04861,Nebivolol
,9131955,AUC,"Cimetidine significantly (p < 0.05) increased the AUC [mean +/- s.d. (95% C.I. of differences in mean)] for unchanged (+/-)-nebivolol [7.76 +/- 3.07 ng ml-1 h with placebo; 11.50 +/- 5.40 (1.75, 8.76) ng ml-1 h with cimetidine], (+)-nebivolol plus its hydroxylated metabolites [73.0 +/- 18.0 ng ml-1 h with placebo; 91.5 +/- 25.7 (1.0, 23.1) ng ml-1 h with cimetidine] and (-)-nebivolol plus its hydroxylated metabolites [101 +/- 32 ng ml-1 h with placebo; 123 +/- 38 (3.3, 27.0) ng ml-1 h with cimetidine].",A pharmacokinetic and pharmacodynamic interaction study between nebivolol and the H2-receptor antagonists cimetidine and ranitidine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9131955/),[h·ng] / [ml],123,35045,DB04861,Nebivolol
,31623262,viscosity,"The physicochemical properties of F7 (pH: 7.1 ± 0.15, viscosity: 8943 ± 116 centipoise, drug content: 98.81% ± 2.16%) seem ideal for transdermal application.",Gellan Gum-Based Hydrogel for the Transdermal Delivery of Nebivolol: Optimization and Evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31623262/),centipoise,8943,86770,DB04861,Nebivolol
,31623262,transdermal flux,Greater transdermal flux (30.86 ± 4.08 µg/cm2/h) was observed in F7 as compared with other prepared gels.,Gellan Gum-Based Hydrogel for the Transdermal Delivery of Nebivolol: Optimization and Evaluation. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31623262/),[μg] / [cm2·h],30.86,86771,DB04861,Nebivolol
,31623262,AUC0-α,Noticeable enhancement in AUC0-α value (986.52 ± 382.63 ng.h/ml; p < 0.01) of transdermal therapy (~2-fold higher compared with oral administration) established the potential of F7 to improve the rate and extent of nebivolol delivery.,Gellan Gum-Based Hydrogel for the Transdermal Delivery of Nebivolol: Optimization and Evaluation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31623262/),[h·ng] / [ml],986.52,86772,DB04861,Nebivolol
,24845234,peak plasma concentrations (Cmax ),Pretreatment with paroxetine increased the mean peak plasma concentrations (Cmax ) for unchanged nebivolol (1·78 ± 1·17 vs. 4·24 ± 1·67 ng/mL) and for its active metabolite (0·58 ± 0·21 vs. 0·79 ± 0·24 ng/mL) compared to nebivolol alone.,A pharmacokinetic drug interaction study between nebivolol and paroxetine in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24845234/),[ng] / [ml],1·78,88983,DB04861,Nebivolol
,24845234,peak plasma concentrations (Cmax ),Pretreatment with paroxetine increased the mean peak plasma concentrations (Cmax ) for unchanged nebivolol (1·78 ± 1·17 vs. 4·24 ± 1·67 ng/mL) and for its active metabolite (0·58 ± 0·21 vs. 0·79 ± 0·24 ng/mL) compared to nebivolol alone.,A pharmacokinetic drug interaction study between nebivolol and paroxetine in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24845234/),[ng] / [ml],4·24,88984,DB04861,Nebivolol
,24845234,peak plasma concentrations (Cmax ),Pretreatment with paroxetine increased the mean peak plasma concentrations (Cmax ) for unchanged nebivolol (1·78 ± 1·17 vs. 4·24 ± 1·67 ng/mL) and for its active metabolite (0·58 ± 0·21 vs. 0·79 ± 0·24 ng/mL) compared to nebivolol alone.,A pharmacokinetic drug interaction study between nebivolol and paroxetine in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24845234/),[ng] / [ml],0·58,88985,DB04861,Nebivolol
,24845234,peak plasma concentrations (Cmax ),Pretreatment with paroxetine increased the mean peak plasma concentrations (Cmax ) for unchanged nebivolol (1·78 ± 1·17 vs. 4·24 ± 1·67 ng/mL) and for its active metabolite (0·58 ± 0·21 vs. 0·79 ± 0·24 ng/mL) compared to nebivolol alone.,A pharmacokinetic drug interaction study between nebivolol and paroxetine in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24845234/),[ng] / [ml],0·79,88986,DB04861,Nebivolol
,24845234,time (tmax ) to reach Cmax,"The time (tmax ) to reach Cmax was 1·37 ± 0·88 (h) and 3·11 ± 1·76 (h) for the parent compound and its active metabolite after nebivolol administered alone and 3·96 ± 1·76 (h), respectively, 7·33 ± 7·84 (h) after pretreatment with paroxetine.",A pharmacokinetic drug interaction study between nebivolol and paroxetine in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24845234/),h,1·37,88987,DB04861,Nebivolol
,24845234,time (tmax ) to reach Cmax,"The time (tmax ) to reach Cmax was 1·37 ± 0·88 (h) and 3·11 ± 1·76 (h) for the parent compound and its active metabolite after nebivolol administered alone and 3·96 ± 1·76 (h), respectively, 7·33 ± 7·84 (h) after pretreatment with paroxetine.",A pharmacokinetic drug interaction study between nebivolol and paroxetine in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24845234/),h,3·11,88988,DB04861,Nebivolol
,24845234,time (tmax ) to reach Cmax,"The time (tmax ) to reach Cmax was 1·37 ± 0·88 (h) and 3·11 ± 1·76 (h) for the parent compound and its active metabolite after nebivolol administered alone and 3·96 ± 1·76 (h), respectively, 7·33 ± 7·84 (h) after pretreatment with paroxetine.",A pharmacokinetic drug interaction study between nebivolol and paroxetine in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24845234/),h,3·96,88989,DB04861,Nebivolol
,24845234,time (tmax ) to reach Cmax,"The time (tmax ) to reach Cmax was 1·37 ± 0·88 (h) and 3·11 ± 1·76 (h) for the parent compound and its active metabolite after nebivolol administered alone and 3·96 ± 1·76 (h), respectively, 7·33 ± 7·84 (h) after pretreatment with paroxetine.",A pharmacokinetic drug interaction study between nebivolol and paroxetine in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24845234/),h,7·33,88990,DB04861,Nebivolol
,24845234,total areas under the curve (AUC0-∞ ),"Also, the total areas under the curve (AUC0-∞ ) were significantly increased from 17·26 ± 43·06 to 106·20 ± 65·56 h ng/mL for nebivolol unchanged and 13·03 ± 11·29 to 74·56 ± 88·77 h ng/mL for its hydroxylated metabolite, before and after paroxetine intake.",A pharmacokinetic drug interaction study between nebivolol and paroxetine in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24845234/),[h·ng] / [ml],17·26,88991,DB04861,Nebivolol
,24845234,total areas under the curve (AUC0-∞ ),"Also, the total areas under the curve (AUC0-∞ ) were significantly increased from 17·26 ± 43·06 to 106·20 ± 65·56 h ng/mL for nebivolol unchanged and 13·03 ± 11·29 to 74·56 ± 88·77 h ng/mL for its hydroxylated metabolite, before and after paroxetine intake.",A pharmacokinetic drug interaction study between nebivolol and paroxetine in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24845234/),[h·ng] / [ml],106·20,88992,DB04861,Nebivolol
,24845234,total areas under the curve (AUC0-∞ ),"Also, the total areas under the curve (AUC0-∞ ) were significantly increased from 17·26 ± 43·06 to 106·20 ± 65·56 h ng/mL for nebivolol unchanged and 13·03 ± 11·29 to 74·56 ± 88·77 h ng/mL for its hydroxylated metabolite, before and after paroxetine intake.",A pharmacokinetic drug interaction study between nebivolol and paroxetine in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24845234/),[h·ng] / [ml],13·03,88993,DB04861,Nebivolol
,24845234,total areas under the curve (AUC0-∞ ),"Also, the total areas under the curve (AUC0-∞ ) were significantly increased from 17·26 ± 43·06 to 106·20 ± 65·56 h ng/mL for nebivolol unchanged and 13·03 ± 11·29 to 74·56 ± 88·77 h ng/mL for its hydroxylated metabolite, before and after paroxetine intake.",A pharmacokinetic drug interaction study between nebivolol and paroxetine in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24845234/),[h·ng] / [ml],74·56,88994,DB04861,Nebivolol
,26914703,area under the concentration-time curve (AUC),CKD increased the area under the concentration-time curve (AUC) of l-nebivolol (6.83 ng.h ml(-1) vs. 9.94 ng.h ml(-1) ) and d-nebivolol (4.15 ng.h ml(-1) vs. 7.30 ng.h ml(-1) ) when compared with the control group.,Influence of chronic kidney disease and haemodialysis treatment on pharmacokinetics of nebivolol enantiomers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26914703/),[h·ng] / [ml],6.83,92264,DB04861,Nebivolol
,26914703,area under the concentration-time curve (AUC),CKD increased the area under the concentration-time curve (AUC) of l-nebivolol (6.83 ng.h ml(-1) vs. 9.94 ng.h ml(-1) ) and d-nebivolol (4.15 ng.h ml(-1) vs. 7.30 ng.h ml(-1) ) when compared with the control group.,Influence of chronic kidney disease and haemodialysis treatment on pharmacokinetics of nebivolol enantiomers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26914703/),[h·ng] / [ml],9.94,92265,DB04861,Nebivolol
,26914703,area under the concentration-time curve (AUC),CKD increased the area under the concentration-time curve (AUC) of l-nebivolol (6.83 ng.h ml(-1) vs. 9.94 ng.h ml(-1) ) and d-nebivolol (4.15 ng.h ml(-1) vs. 7.30 ng.h ml(-1) ) when compared with the control group.,Influence of chronic kidney disease and haemodialysis treatment on pharmacokinetics of nebivolol enantiomers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26914703/),[h·ng] / [ml],4.15,92266,DB04861,Nebivolol
,26914703,area under the concentration-time curve (AUC),CKD increased the area under the concentration-time curve (AUC) of l-nebivolol (6.83 ng.h ml(-1) vs. 9.94 ng.h ml(-1) ) and d-nebivolol (4.15 ng.h ml(-1) vs. 7.30 ng.h ml(-1) ) when compared with the control group.,Influence of chronic kidney disease and haemodialysis treatment on pharmacokinetics of nebivolol enantiomers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26914703/),[h·ng] / [ml],7.30,92267,DB04861,Nebivolol
,26914703,AUC,"However, the AUC values of l-nebivolol (6.41 ng.h ml(-1) ) and d-nebivolol (4.95 ng.h ml(-1) ) did not differ between the haemodialysis and control groups.",Influence of chronic kidney disease and haemodialysis treatment on pharmacokinetics of nebivolol enantiomers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26914703/),[h·ng] / [ml],6.41,92268,DB04861,Nebivolol
,26914703,AUC,"However, the AUC values of l-nebivolol (6.41 ng.h ml(-1) ) and d-nebivolol (4.95 ng.h ml(-1) ) did not differ between the haemodialysis and control groups.",Influence of chronic kidney disease and haemodialysis treatment on pharmacokinetics of nebivolol enantiomers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26914703/),[h·ng] / [ml],4.95,92269,DB04861,Nebivolol
,24141040,AUC(0-∞),Isomer l-nebivolol showed higher AUC(0-∞) (9.4ng/h/mL vs. 4.7ng/h/mL) and smaller apparent clearance (Cl/f) (531.8L/h vs. 1304.4L/h) when compared to antipode d-nebivolol.,Stereoselective analysis of nebivolol isomers in human plasma by high-performance liquid chromatography-tandem mass spectrometry: application in pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24141040/),[ng] / [h·ml],9.4,130306,DB04861,Nebivolol
,24141040,AUC(0-∞),Isomer l-nebivolol showed higher AUC(0-∞) (9.4ng/h/mL vs. 4.7ng/h/mL) and smaller apparent clearance (Cl/f) (531.8L/h vs. 1304.4L/h) when compared to antipode d-nebivolol.,Stereoselective analysis of nebivolol isomers in human plasma by high-performance liquid chromatography-tandem mass spectrometry: application in pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24141040/),[ng] / [h·ml],4.7,130307,DB04861,Nebivolol
,24141040,apparent clearance (Cl/f),Isomer l-nebivolol showed higher AUC(0-∞) (9.4ng/h/mL vs. 4.7ng/h/mL) and smaller apparent clearance (Cl/f) (531.8L/h vs. 1304.4L/h) when compared to antipode d-nebivolol.,Stereoselective analysis of nebivolol isomers in human plasma by high-performance liquid chromatography-tandem mass spectrometry: application in pharmacokinetics. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24141040/),[l] / [h],531.8,130308,DB04861,Nebivolol
,24141040,apparent clearance (Cl/f),Isomer l-nebivolol showed higher AUC(0-∞) (9.4ng/h/mL vs. 4.7ng/h/mL) and smaller apparent clearance (Cl/f) (531.8L/h vs. 1304.4L/h) when compared to antipode d-nebivolol.,Stereoselective analysis of nebivolol isomers in human plasma by high-performance liquid chromatography-tandem mass spectrometry: application in pharmacokinetics. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24141040/),[l] / [h],1304.4,130309,DB04861,Nebivolol
,9112066,distribution volume at steady state (Vss),The main pharmacokinetic parameters of unchanged nebivolol in extensive metabolizers were (controls): distribution volume at steady state (Vss) 673 l; volume corrected by real body weight (Vss.kg-1) 11.2 l.kg-1; total clearance (CL) 51.6 h-1; and terminal half-life (t1/2) 10.3 h.,Pharmacokinetic study and cardiovascular monitoring of nebivolol in normal and obese subjects. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9112066/),l,673,145242,DB04861,Nebivolol
,9112066,volume corrected by real body weight (Vss.kg-1),The main pharmacokinetic parameters of unchanged nebivolol in extensive metabolizers were (controls): distribution volume at steady state (Vss) 673 l; volume corrected by real body weight (Vss.kg-1) 11.2 l.kg-1; total clearance (CL) 51.6 h-1; and terminal half-life (t1/2) 10.3 h.,Pharmacokinetic study and cardiovascular monitoring of nebivolol in normal and obese subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9112066/),[l] / [kg],11.2,145243,DB04861,Nebivolol
,9112066,total clearance (CL),The main pharmacokinetic parameters of unchanged nebivolol in extensive metabolizers were (controls): distribution volume at steady state (Vss) 673 l; volume corrected by real body weight (Vss.kg-1) 11.2 l.kg-1; total clearance (CL) 51.6 h-1; and terminal half-life (t1/2) 10.3 h.,Pharmacokinetic study and cardiovascular monitoring of nebivolol in normal and obese subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9112066/),1/[h],51.6,145244,DB04861,Nebivolol
,9112066,terminal half-life (t1/2),The main pharmacokinetic parameters of unchanged nebivolol in extensive metabolizers were (controls): distribution volume at steady state (Vss) 673 l; volume corrected by real body weight (Vss.kg-1) 11.2 l.kg-1; total clearance (CL) 51.6 h-1; and terminal half-life (t1/2) 10.3 h.,Pharmacokinetic study and cardiovascular monitoring of nebivolol in normal and obese subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9112066/),h,10.3,145245,DB04861,Nebivolol
,9112066,Vss,The Vss (898 l) and CL (71.6 l.h-1) were significantly higher in obese patients.,Pharmacokinetic study and cardiovascular monitoring of nebivolol in normal and obese subjects. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9112066/),l,898,145246,DB04861,Nebivolol
,9112066,CL,The Vss (898 l) and CL (71.6 l.h-1) were significantly higher in obese patients.,Pharmacokinetic study and cardiovascular monitoring of nebivolol in normal and obese subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9112066/),[l] / [h],71.6,145247,DB04861,Nebivolol
,9112066,Vss.kg-1,But Vss.kg-1 (9.4 l.kg-1) and t1/2 (10.0 h) were not significantly different from those in controls.,Pharmacokinetic study and cardiovascular monitoring of nebivolol in normal and obese subjects. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9112066/),[l] / [kg],9.4,145248,DB04861,Nebivolol
,9112066,t1/2,But Vss.kg-1 (9.4 l.kg-1) and t1/2 (10.0 h) were not significantly different from those in controls.,Pharmacokinetic study and cardiovascular monitoring of nebivolol in normal and obese subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9112066/),h,10.0,145249,DB04861,Nebivolol
,9112066,CL,"The CL was clearly reduced (15-18 l.h-1) and the t1/2 prolonged (32-34 h) in poor hydroxylators, in both control and obese subjects.",Pharmacokinetic study and cardiovascular monitoring of nebivolol in normal and obese subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9112066/),[l] / [h],15-18,145250,DB04861,Nebivolol
,9112066,t1/2,"The CL was clearly reduced (15-18 l.h-1) and the t1/2 prolonged (32-34 h) in poor hydroxylators, in both control and obese subjects.",Pharmacokinetic study and cardiovascular monitoring of nebivolol in normal and obese subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9112066/),h,32-34,145251,DB04861,Nebivolol
,28209351,AUC,"Regarding to the nebivolol glucuronide isomers, higher plasma concentrations of the d-isomer were observed compared to the l-isomer (d/l AUC=5.4), explaining at least in part the plasma accumulation of unchanged l-nebivolol (l/d AUC=1.8).",An indirect stereoselective analysis of nebivolol glucuronides in plasma by LC-MS/MS: Application to clinical pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28209351/),,5.4,179615,DB04861,Nebivolol
,28209351,AUC,"Regarding to the nebivolol glucuronide isomers, higher plasma concentrations of the d-isomer were observed compared to the l-isomer (d/l AUC=5.4), explaining at least in part the plasma accumulation of unchanged l-nebivolol (l/d AUC=1.8).",An indirect stereoselective analysis of nebivolol glucuronides in plasma by LC-MS/MS: Application to clinical pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28209351/),,1.8,179616,DB04861,Nebivolol
,28209351,ratios,This study also showed metabolic glucuronide nebivolol/unchanged nebivolol ratios of approximately 6.5 for the l-isomer (AUC 65.3 vs 10.1ngh/mL) and approximately 62.1 (335.2 vs 5.4ngh/mL) for the d-isomer.,An indirect stereoselective analysis of nebivolol glucuronides in plasma by LC-MS/MS: Application to clinical pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28209351/),,6.5,179617,DB04861,Nebivolol
,28209351,AUC,This study also showed metabolic glucuronide nebivolol/unchanged nebivolol ratios of approximately 6.5 for the l-isomer (AUC 65.3 vs 10.1ngh/mL) and approximately 62.1 (335.2 vs 5.4ngh/mL) for the d-isomer.,An indirect stereoselective analysis of nebivolol glucuronides in plasma by LC-MS/MS: Application to clinical pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28209351/),[ngh] / [ml],65.3,179618,DB04861,Nebivolol
,28209351,AUC,This study also showed metabolic glucuronide nebivolol/unchanged nebivolol ratios of approximately 6.5 for the l-isomer (AUC 65.3 vs 10.1ngh/mL) and approximately 62.1 (335.2 vs 5.4ngh/mL) for the d-isomer.,An indirect stereoselective analysis of nebivolol glucuronides in plasma by LC-MS/MS: Application to clinical pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28209351/),[ngh] / [ml],10.1,179619,DB04861,Nebivolol
,28209351,AUC,This study also showed metabolic glucuronide nebivolol/unchanged nebivolol ratios of approximately 6.5 for the l-isomer (AUC 65.3 vs 10.1ngh/mL) and approximately 62.1 (335.2 vs 5.4ngh/mL) for the d-isomer.,An indirect stereoselective analysis of nebivolol glucuronides in plasma by LC-MS/MS: Application to clinical pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28209351/),[ngh] / [ml],62.1,179620,DB04861,Nebivolol
,28209351,AUC,This study also showed metabolic glucuronide nebivolol/unchanged nebivolol ratios of approximately 6.5 for the l-isomer (AUC 65.3 vs 10.1ngh/mL) and approximately 62.1 (335.2 vs 5.4ngh/mL) for the d-isomer.,An indirect stereoselective analysis of nebivolol glucuronides in plasma by LC-MS/MS: Application to clinical pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28209351/),[ngh] / [ml],335.2,179621,DB04861,Nebivolol
,28209351,AUC,This study also showed metabolic glucuronide nebivolol/unchanged nebivolol ratios of approximately 6.5 for the l-isomer (AUC 65.3 vs 10.1ngh/mL) and approximately 62.1 (335.2 vs 5.4ngh/mL) for the d-isomer.,An indirect stereoselective analysis of nebivolol glucuronides in plasma by LC-MS/MS: Application to clinical pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28209351/),[ngh] / [ml],5.4,179622,DB04861,Nebivolol
,21840269,flow rate,"An aliquot of 150 μl of plasma sample was introduced into the pretreatment column via the auto sampler using mobile phase 1 at a flow rate of 0.5 ml/min, column switching valve being positioned at A.",High performance liquid chromatographic method for the determination of cetirizine and ambroxol in human plasma and urine--a boxcar approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21840269/),[ml] / [min],0.5,185335,DB04861,Nebivolol
,21840269,flow rate,"Finally, cetirizine, ambroxol and IS were introduced to the separation column by switching valve using mobile phase 2 at a flow rate of 0.4 ml/min.",High performance liquid chromatographic method for the determination of cetirizine and ambroxol in human plasma and urine--a boxcar approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21840269/),[ml] / [min],0.4,185336,DB04861,Nebivolol
,21840269,total run time,The total run time was 25 min for a sample.,High performance liquid chromatographic method for the determination of cetirizine and ambroxol in human plasma and urine--a boxcar approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21840269/),min,25,185337,DB04861,Nebivolol
,31862675,recovery (%),"Mean recovery (%) values in aqueous humor and plasma were 72.4% and 73.0% for nebivolol and 56.7% and 54.4% for labetalol, respectively.",Development and validation of a bio-analytical method for simultaneous quantification of nebivolol and labetalol in aqueous humor and plasma using LC-MS/MS and its application to ocular pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31862675/),%,72.4,187766,DB04861,Nebivolol
,31862675,recovery (%),"Mean recovery (%) values in aqueous humor and plasma were 72.4% and 73.0% for nebivolol and 56.7% and 54.4% for labetalol, respectively.",Development and validation of a bio-analytical method for simultaneous quantification of nebivolol and labetalol in aqueous humor and plasma using LC-MS/MS and its application to ocular pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31862675/),%,73.0,187767,DB04861,Nebivolol
,31862675,recovery (%),"Mean recovery (%) values in aqueous humor and plasma were 72.4% and 73.0% for nebivolol and 56.7% and 54.4% for labetalol, respectively.",Development and validation of a bio-analytical method for simultaneous quantification of nebivolol and labetalol in aqueous humor and plasma using LC-MS/MS and its application to ocular pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31862675/),%,56.7,187768,DB04861,Nebivolol
,31862675,recovery (%),"Mean recovery (%) values in aqueous humor and plasma were 72.4% and 73.0% for nebivolol and 56.7% and 54.4% for labetalol, respectively.",Development and validation of a bio-analytical method for simultaneous quantification of nebivolol and labetalol in aqueous humor and plasma using LC-MS/MS and its application to ocular pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31862675/),%,54.4,187769,DB04861,Nebivolol
,27300331,peak plasma concentrations (Cmax),Bupropion plus nebivolol increased the mean peak plasma concentrations (Cmax) of nebivolol (1.67 ± 0.69 vs. 3.80 ± 1.70 ng/ml) and its active metabolite (0.68 ± 0.22 vs. 1.13 ± 0.38 ng/ml) compared to nebivolol alone.,Assessment of a Potential Pharmacokinetic Interaction between Nebivolol and Bupropion in Healthy Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27300331/),[ng] / [ml],1.67,189481,DB04861,Nebivolol
,27300331,peak plasma concentrations (Cmax),Bupropion plus nebivolol increased the mean peak plasma concentrations (Cmax) of nebivolol (1.67 ± 0.69 vs. 3.80 ± 1.70 ng/ml) and its active metabolite (0.68 ± 0.22 vs. 1.13 ± 0.38 ng/ml) compared to nebivolol alone.,Assessment of a Potential Pharmacokinetic Interaction between Nebivolol and Bupropion in Healthy Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27300331/),[ng] / [ml],3.80,189482,DB04861,Nebivolol
,27300331,peak plasma concentrations (Cmax),Bupropion plus nebivolol increased the mean peak plasma concentrations (Cmax) of nebivolol (1.67 ± 0.69 vs. 3.80 ± 1.70 ng/ml) and its active metabolite (0.68 ± 0.22 vs. 1.13 ± 0.38 ng/ml) compared to nebivolol alone.,Assessment of a Potential Pharmacokinetic Interaction between Nebivolol and Bupropion in Healthy Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27300331/),[ng] / [ml],0.68,189483,DB04861,Nebivolol
,27300331,peak plasma concentrations (Cmax),Bupropion plus nebivolol increased the mean peak plasma concentrations (Cmax) of nebivolol (1.67 ± 0.69 vs. 3.80 ± 1.70 ng/ml) and its active metabolite (0.68 ± 0.22 vs. 1.13 ± 0.38 ng/ml) compared to nebivolol alone.,Assessment of a Potential Pharmacokinetic Interaction between Nebivolol and Bupropion in Healthy Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27300331/),[ng] / [ml],1.13,189484,DB04861,Nebivolol
,26444187,Encapsulation efficiencies (EEs),Encapsulation efficiencies (EEs) were determined as 84-98%.,Modification of solid lipid nanoparticles loaded with nebivolol hydrochloride for improvement of oral bioavailability in treatment of hypertension: polyethylene glycol versus chitosan oligosaccharide lactate. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26444187/),%,84-98,191269,DB04861,Nebivolol
,16006083,runtime,"The chromatographic runtime was 2 min and the weighted (1/x2) calibration curves were linear over the range 50-10,000 pg/mL.",Rapid quantification of nebivolol in human plasma by liquid chromatography coupled with electrospray ionization tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16006083/),min,2,192244,DB04861,Nebivolol
,16006083,limit of detection,"The limit of detection and lower limit of quantification in human plasma were 10 and 50 pg/mL, respectively.",Rapid quantification of nebivolol in human plasma by liquid chromatography coupled with electrospray ionization tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16006083/),[pg] / [ml],10,192245,DB04861,Nebivolol
,16006083,absolute recoveries,"The average absolute recoveries of nebivolol and tamsulosin, used as an internal standard, from spiked plasma samples were 73.4+/-3.7 and 72.1+/-2.0%, respectively.",Rapid quantification of nebivolol in human plasma by liquid chromatography coupled with electrospray ionization tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16006083/),%,73.4,192246,DB04861,Nebivolol
,16006083,absolute recoveries,"The average absolute recoveries of nebivolol and tamsulosin, used as an internal standard, from spiked plasma samples were 73.4+/-3.7 and 72.1+/-2.0%, respectively.",Rapid quantification of nebivolol in human plasma by liquid chromatography coupled with electrospray ionization tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16006083/),%,72.1,192247,DB04861,Nebivolol
,29676238,C,"For d-nebivolol, Cmax, Tmax and AUC0-48 were, on average, 5.9, 2.7 and 15.0 larger in PMs.",Effect of CYP2D6 Poor Metabolizer Phenotype on Stereoselective Nebivolol Pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29676238/),,5.9,202498,DB04861,Nebivolol
,29676238,Tmax,"For d-nebivolol, Cmax, Tmax and AUC0-48 were, on average, 5.9, 2.7 and 15.0 larger in PMs.",Effect of CYP2D6 Poor Metabolizer Phenotype on Stereoselective Nebivolol Pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29676238/),,2,202499,DB04861,Nebivolol
,28459657,Cmax,Fluvoxamine pretreatment increased Cmax and AUC0-∞ of nebivolol (Cmax: 1.67 ± 0.690 vs 2.20 ± 0.970 ng/mL; AUC0-∞: 12.1 ± 11.0 vs 19.3 ± 19.5 ng*h/mL ) and of its active metabolite (Cmax: 0.680 ± 0.220 vs 0.960 ± 0.290 ng/mL; AUC0-∞: 17.6 ±20.1 vs 25.5 ± 29.9 ng*h/mL).,Investigation of a Potential Pharmacokinetic Interaction Between Nebivolol and Fluvoxamine in Healthy Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28459657/),[ng] / [ml],1.67,203286,DB04861,Nebivolol
,28459657,Cmax,Fluvoxamine pretreatment increased Cmax and AUC0-∞ of nebivolol (Cmax: 1.67 ± 0.690 vs 2.20 ± 0.970 ng/mL; AUC0-∞: 12.1 ± 11.0 vs 19.3 ± 19.5 ng*h/mL ) and of its active metabolite (Cmax: 0.680 ± 0.220 vs 0.960 ± 0.290 ng/mL; AUC0-∞: 17.6 ±20.1 vs 25.5 ± 29.9 ng*h/mL).,Investigation of a Potential Pharmacokinetic Interaction Between Nebivolol and Fluvoxamine in Healthy Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28459657/),[ng] / [ml],2.20,203287,DB04861,Nebivolol
,28459657,AUC0-∞,Fluvoxamine pretreatment increased Cmax and AUC0-∞ of nebivolol (Cmax: 1.67 ± 0.690 vs 2.20 ± 0.970 ng/mL; AUC0-∞: 12.1 ± 11.0 vs 19.3 ± 19.5 ng*h/mL ) and of its active metabolite (Cmax: 0.680 ± 0.220 vs 0.960 ± 0.290 ng/mL; AUC0-∞: 17.6 ±20.1 vs 25.5 ± 29.9 ng*h/mL).,Investigation of a Potential Pharmacokinetic Interaction Between Nebivolol and Fluvoxamine in Healthy Volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28459657/),[h·ng] / [ml],12.1,203288,DB04861,Nebivolol
,28459657,AUC0-∞,Fluvoxamine pretreatment increased Cmax and AUC0-∞ of nebivolol (Cmax: 1.67 ± 0.690 vs 2.20 ± 0.970 ng/mL; AUC0-∞: 12.1 ± 11.0 vs 19.3 ± 19.5 ng*h/mL ) and of its active metabolite (Cmax: 0.680 ± 0.220 vs 0.960 ± 0.290 ng/mL; AUC0-∞: 17.6 ±20.1 vs 25.5 ± 29.9 ng*h/mL).,Investigation of a Potential Pharmacokinetic Interaction Between Nebivolol and Fluvoxamine in Healthy Volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28459657/),[h·ng] / [ml],19.3,203289,DB04861,Nebivolol
,28459657,Cmax,Fluvoxamine pretreatment increased Cmax and AUC0-∞ of nebivolol (Cmax: 1.67 ± 0.690 vs 2.20 ± 0.970 ng/mL; AUC0-∞: 12.1 ± 11.0 vs 19.3 ± 19.5 ng*h/mL ) and of its active metabolite (Cmax: 0.680 ± 0.220 vs 0.960 ± 0.290 ng/mL; AUC0-∞: 17.6 ±20.1 vs 25.5 ± 29.9 ng*h/mL).,Investigation of a Potential Pharmacokinetic Interaction Between Nebivolol and Fluvoxamine in Healthy Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28459657/),[ng] / [ml],0.680,203290,DB04861,Nebivolol
,28459657,Cmax,Fluvoxamine pretreatment increased Cmax and AUC0-∞ of nebivolol (Cmax: 1.67 ± 0.690 vs 2.20 ± 0.970 ng/mL; AUC0-∞: 12.1 ± 11.0 vs 19.3 ± 19.5 ng*h/mL ) and of its active metabolite (Cmax: 0.680 ± 0.220 vs 0.960 ± 0.290 ng/mL; AUC0-∞: 17.6 ±20.1 vs 25.5 ± 29.9 ng*h/mL).,Investigation of a Potential Pharmacokinetic Interaction Between Nebivolol and Fluvoxamine in Healthy Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28459657/),[ng] / [ml],0.960,203291,DB04861,Nebivolol
,28459657,AUC0-∞,Fluvoxamine pretreatment increased Cmax and AUC0-∞ of nebivolol (Cmax: 1.67 ± 0.690 vs 2.20 ± 0.970 ng/mL; AUC0-∞: 12.1 ± 11.0 vs 19.3 ± 19.5 ng*h/mL ) and of its active metabolite (Cmax: 0.680 ± 0.220 vs 0.960 ± 0.290 ng/mL; AUC0-∞: 17.6 ±20.1 vs 25.5 ± 29.9 ng*h/mL).,Investigation of a Potential Pharmacokinetic Interaction Between Nebivolol and Fluvoxamine in Healthy Volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28459657/),[h·ng] / [ml],17.6,203292,DB04861,Nebivolol
,28459657,AUC0-∞,Fluvoxamine pretreatment increased Cmax and AUC0-∞ of nebivolol (Cmax: 1.67 ± 0.690 vs 2.20 ± 0.970 ng/mL; AUC0-∞: 12.1 ± 11.0 vs 19.3 ± 19.5 ng*h/mL ) and of its active metabolite (Cmax: 0.680 ± 0.220 vs 0.960 ± 0.290 ng/mL; AUC0-∞: 17.6 ±20.1 vs 25.5 ± 29.9 ng*h/mL).,Investigation of a Potential Pharmacokinetic Interaction Between Nebivolol and Fluvoxamine in Healthy Volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28459657/),[h·ng] / [ml],25.5,203293,DB04861,Nebivolol
,9010695,venous volume,"Following the first dose the venous volume was higher on placebo (5.88 ml.100 ml-1 tissue) as compared to active nebivolol treatment (5.17 ml.100 ml-1 tissue), while there were no statistically significant differences with regard to venous plethysmographic findings after 1 month on placebo (5.53 ml.100 ml-1 tissue) or on active treatment (5.97 ml.100 ml-1 tissue).",Haemodynamic effects and pharmacokinetics of oral d- and l-nebivolol in hypertensive patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010695/),[100·ml·tissue] / [ml],5.88,205656,DB04861,Nebivolol
,9010695,venous volume,"Following the first dose the venous volume was higher on placebo (5.88 ml.100 ml-1 tissue) as compared to active nebivolol treatment (5.17 ml.100 ml-1 tissue), while there were no statistically significant differences with regard to venous plethysmographic findings after 1 month on placebo (5.53 ml.100 ml-1 tissue) or on active treatment (5.97 ml.100 ml-1 tissue).",Haemodynamic effects and pharmacokinetics of oral d- and l-nebivolol in hypertensive patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010695/),[100·ml·tissue] / [ml],5.17,205657,DB04861,Nebivolol
,9010695,venous volume,"Following the first dose the venous volume was higher on placebo (5.88 ml.100 ml-1 tissue) as compared to active nebivolol treatment (5.17 ml.100 ml-1 tissue), while there were no statistically significant differences with regard to venous plethysmographic findings after 1 month on placebo (5.53 ml.100 ml-1 tissue) or on active treatment (5.97 ml.100 ml-1 tissue).",Haemodynamic effects and pharmacokinetics of oral d- and l-nebivolol in hypertensive patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010695/),100·ml,5.53,205658,DB04861,Nebivolol
,9010695,venous volume,"Following the first dose the venous volume was higher on placebo (5.88 ml.100 ml-1 tissue) as compared to active nebivolol treatment (5.17 ml.100 ml-1 tissue), while there were no statistically significant differences with regard to venous plethysmographic findings after 1 month on placebo (5.53 ml.100 ml-1 tissue) or on active treatment (5.97 ml.100 ml-1 tissue).",Haemodynamic effects and pharmacokinetics of oral d- and l-nebivolol in hypertensive patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010695/),[tissue] / [ml],5.97,205659,DB04861,Nebivolol
,9010695,peripheral resistance,"Calculated peripheral resistance did not differ between active treatment (617 units) or placebo (548 units) after the first dose, whereas it was significantly lowered after 4 weeks of nebivolol treatment (483 units) as compared to placebo (593 units).",Haemodynamic effects and pharmacokinetics of oral d- and l-nebivolol in hypertensive patients. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010695/),units,617,205660,DB04861,Nebivolol
,9010695,peripheral resistance,"Calculated peripheral resistance did not differ between active treatment (617 units) or placebo (548 units) after the first dose, whereas it was significantly lowered after 4 weeks of nebivolol treatment (483 units) as compared to placebo (593 units).",Haemodynamic effects and pharmacokinetics of oral d- and l-nebivolol in hypertensive patients. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010695/),units,548,205661,DB04861,Nebivolol
,9010695,peripheral resistance,"Calculated peripheral resistance did not differ between active treatment (617 units) or placebo (548 units) after the first dose, whereas it was significantly lowered after 4 weeks of nebivolol treatment (483 units) as compared to placebo (593 units).",Haemodynamic effects and pharmacokinetics of oral d- and l-nebivolol in hypertensive patients. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010695/),units,483,205662,DB04861,Nebivolol
,9010695,peripheral resistance,"Calculated peripheral resistance did not differ between active treatment (617 units) or placebo (548 units) after the first dose, whereas it was significantly lowered after 4 weeks of nebivolol treatment (483 units) as compared to placebo (593 units).",Haemodynamic effects and pharmacokinetics of oral d- and l-nebivolol in hypertensive patients. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010695/),units,593,205663,DB04861,Nebivolol
